In addition to their improved tropism for the target tissues ... the dorsal root ganglia or the liver, which may help avoid toxicities commonly associated with AAV delivery.

In addition to muscle-targeting AAVs with reduced liver off-targeting, the team has developed AAV serotypes that target human primary T cells, which could be of interest for developing CAR-T-cell ...

the structures that envelop genetic material of adeno-associated viruses (AAV), to improve gene therapies for muscle diseases. The new capsids effectively target the muscle and avoid the liver ...

The results underscore the potential of KRIYA-497, an investigational, intramuscularly-administered AAV gene therapy designed to express native fibroblast growth factor 21 (FGF21) protein. Other FGF21 ...